Bradley & Co Private Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$4.24K	–	220
2025 Q3	$4.24K	Hold	1,000	–	–	﹤0.01%	157
2025 Q2	$2.11K	Hold	1,000	–	–	﹤0.01%	172
2025 Q1	$1.22K	Hold	1,000	–	–	﹤0.01%	170
2024 Q4	$1.29K	Buy	+1,000	New	+$2.4K	﹤0.01%	170
2024 Q2	$2.26K	Hold	1,000	–	–	﹤0.01%	156
2024 Q1	$2.39K	Hold	1,000	–	–	﹤0.01%	160
2023 Q4	$1.66K	Hold	1,000	–	–	﹤0.01%	175
2023 Q3	$1.92K	Hold	1,000	–	–	﹤0.01%	157
2023 Q2	$1.44K	Hold	1,000	–	–	﹤0.01%	160
2023 Q1	$2.1K	Hold	1,000	–	–	﹤0.01%	155
2022 Q4	$1.13K	Hold	1,000	–	–	﹤0.01%	162
2022 Q3	$2K	Hold	1,000	–	–	﹤0.01%	166
2022 Q2	$1K	Hold	1,000	–	–	﹤0.01%	177
2022 Q1	$2K	Hold	1,000	–	–	﹤0.01%	143
2021 Q4	$2K	Hold	1,000	–	–	﹤0.01%	148
2021 Q3	$4K	Hold	1,000	–	–	﹤0.01%	147
2021 Q2	$3K	Hold	1,000	–	–	﹤0.01%	152
2021 Q1	$2K	Buy	+1,000	New	+$2.24K	﹤0.01%	158

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bradley & Co Private Wealth Management's GALT Position: Q4 2025 in Review

Bradley & Co Private Wealth Management sold out of Galectin Therapeutics (GALT) in Q4 2025, closing a stake of 1,000 shares — an estimated $4.24K sold.

Bradley & Co Private Wealth Management first reported a position in GALT in Q1 2021 and held it in 18 quarters. The position peaked at $4.24K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q4 2025.

Bradley & Co Private Wealth Management reported no remaining Galectin Therapeutics position as of Q4 2025 after selling out during the quarter.
Bradley & Co Private Wealth Management sold 1,000 Galectin Therapeutics shares in Q4 2025, an estimated $4.24K.
Bradley & Co Private Wealth Management first reported a position in Galectin Therapeutics in Q1 2021 and held it in 18 quarters.
Bradley & Co Private Wealth Management's Galectin Therapeutics position peaked at $4.24K in Q3 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q4 2025.

Based on Bradley & Co Private Wealth Management's 13F filing for Q4 2025, filed 11 Feb 2026.